When exploring dasatinib package insert, it's essential to consider various aspects and implications. SPRYCEL (dasatinib) tablets label - Food and Drug Administration. SPRYCEL tablets are white to off-white, biconvex, film-coated tablets containing dasatinib, with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose,... Prescribing Information - BMS.
SPRYCEL® (dasatinib) - Official Patient Website. This is a summary of important information that patients need to know about SPRYCEL. Your healthcare team can work with you to help answer any questions you may have about SPRYCEL. This perspective suggests that, keep this document in a safe place, so you can refer to it before and during treatment.
Look out for the following icons as you read: Dasatinib: Package Insert / Prescribing Information / MOA. Includes: indications, dosage, adverse reactions and pharmacology. DailyMed - SPRYCEL- dasatinib tablet.
SPRYCEL (dasatinib) Tablets are available as 20-mg, 50-mg, 70-mg, 80-mg, 100-mg, and 140-mg white to off-white, biconvex, film-coated tablets. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include .... For patients taking dasatinib tablets 60 mg or 40 mg daily, consider interrupting dasatinib tablets until the inhibitor is discontinued.
Allow a washout period of approximately 1 week after the inhibitor is stopped before reinitiating dasatinib tablets. Treatment with dasatinib is associated with severe (NCI CTCAE Grade 3 or 4) thrombocytopenia, neutropenia, and anemia, which occur earlier and more frequently in patients with advanced phase CML or Ph+ ALL than in patients with chronic phase CML [see Adverse Reactions (6.1)]. Sprycel (dasatinib) [package insert]. | Molecular Oncology Almanac. Regulatory approval published by the Food and Drug Administration.
Citation Bristol-Myers Squibb Company. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s027lbl.pdf. Revised February 2023. SPRYCEL® (dasatinib) for Healthcare Professionals.
SPRYCEL ® (dasatinib) is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase Squibb & Sons, L.L.C.): FDA Package Insert. The recommended starting dosage of SPRYCEL for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults is 140 mg administered orally once daily.
📝 Summary
As we've seen, dasatinib package insert represents a crucial area worthy of attention. Moving forward, continued learning on this topic will deliver additional insights and benefits.